Earnings ·
Stoke Therapeutics reported second quarter 2026 financial results and provided business updates
STOKStoke Therapeutics, Inc.
Stoke Therapeutics reported second quarter 2026 financial results and provided business updates. The company generated $9.3 million in revenue, a decrease from $13.8 million in the prior year period, and incurred a net loss of $61.6 million, or $0.93 per share, compared to a net loss of $23.5 million previously. Research and development expenses rose to $49.5 million due to increased activities for zorevunersen. The company holds approximately $420 million in cash and marketable securities, funded by $354.3 million at quarter-end and $65.7 million from a subsequent ATM sale. Clinically, the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome completed enrollment of 162 patients, with data readout anticipated in Q3 2027. A pre-NDA meeting with the FDA is scheduled for H2 2026, and a rolling U.S. NDA submission is planned to initiate in Q1 2027. Additionally, dose escalation continues in the Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA). Stoke Therapeutics operates as a biotechnology company developing RNA medicines.